SCHEMBL6070845

SCHEMBL6070845

O=C1C(=CO)CCc2c1[nH]c1cccc(C(=O)O)c21

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.47
RAB9A P51151 7/20 0.46
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
POLB P06746 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
KDM4E B2RXH2 2/20 0.42
PBRM1 Q86U86 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
GFER P55789 1/20 0.36
HSD17B10 Q99714 1/20 0.33
NAPRT Q6XQN6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6070839 1.00 PARP1 (0.47) PARP1RAB9AMAPTSMN1; SMN2NPC1
SCHEMBL11082468 0.76 RAB9A (0.69) RAB9AMAPTSMN1; SMN2NPC1POLB
SCHEMBL11082466 0.76 RAB9A (0.69) RAB9AMAPTSMN1; SMN2NPC1POLB
SCHEMBL6070313 0.76 HSD17B10 (0.55) PARP1MAPTSMN1; SMN2POLBALDH1A1
SCHEMBL6238374 0.75 PARP1 (0.59) PARP1KDM4EMEN1HTTKMT2A
SCHEMBL6070387 0.72 MAPT (0.51) PARP1RAB9AMAPTSMN1; SMN2NPC1
SCHEMBL6070383 0.72 MAPT (0.51) PARP1RAB9AMAPTSMN1; SMN2NPC1
SCHEMBL6070636 0.70 PARP1 (0.42) PARP1PBRM1GFER
SCHEMBL17715018 0.70 PARP1 (0.50) PARP1SMN1; SMN2ALDH1A1KDM4EPBRM1
SCHEMBL2485381 0.68 GFER (0.60) PARP1MAPTSMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed
EP-1599202-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-11-30 EP disclosed
WO-2004071507-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 PARP1 840/4885RAB9A 1100/4885MAPT 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.